title: Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.
abstract: OBJECTIVE
  To determine the frequency of estrogen receptor alpha and beta and progesterone receptor protein immunohistochemical expression in a large set of non-small cell lung carcinoma (NSCLC) specimens and to compare our results with those for some of the same antibodies that have provided inconsistent results in previously published reports.
  
  
  METHODS
  Using multiple antibodies, we investigated the immunohistochemical expression of estrogen receptors alpha and beta and progesterone receptor in 317 NSCLCs placed in tissue microarrays and correlated their expression with patients' clinicopathologic characteristics and in adenocarcinomas with EGFR mutation status.
  
  
  RESULTS
  Estrogen receptors alpha and beta were detected in the nucleus and cytoplasm of NSCLC cells; however, the frequency of expression (nucleus, 5-36% for alpha and 42-56% for beta; cytoplasm: <1-42% for alpha and 20-98% for beta) varied among the different antibodies tested. Progesterone receptor was expressed in the nuclei of malignant cells in 63% of the tumors. Estrogen receptor alpha nuclear expression significantly correlated with adenocarcinoma histology, female gender, and history of never smoking (P = 0.0048 to <0.0001). In NSCLC, higher cytoplasmic estrogen receptor alpha expression significantly correlated with worse recurrence-free survival (hazard ratio, 1.77; 95% confidence interval, 1.12, 2.82; P = 0.015) in multivariate analysis. In adenocarcinomas, estrogen receptor alpha expression correlated with EGFR mutation (P = 0.0029 to <0.0001). Estrogen receptor beta and progesterone receptor but not estrogen receptor alpha expressed in the normal epithelium adjacent to lung adenocarcinomas.
  
  
  CONCLUSIONS
  Estrogen receptor alpha and beta expression distinguishes a subset of NSCLC that has defined clinicopathologic and genetic features. In lung adenocarcinoma, estrogen receptor alpha expression correlates with EGFR mutations.
authors.affiliation: Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.
authors.forename: Maria G
authors.initials: MG
authors.lastname: Raso
authors.forename: Carmen
authors.initials: C
authors.lastname: Behrens
authors.forename: Matthew H
authors.initials: MH
authors.lastname: Herynk
authors.forename: Suyu
authors.initials: S
authors.lastname: Liu
authors.forename: Ludmila
authors.initials: L
authors.lastname: Prudkin
authors.forename: Natalie C
authors.initials: NC
authors.lastname: Ozburn
authors.forename: Denise M
authors.initials: DM
authors.lastname: Woods
authors.forename: Ximing
authors.initials: X
authors.lastname: Tang
authors.forename: Reza J
authors.initials: RJ
authors.lastname: Mehran
authors.forename: Cesar
authors.initials: C
authors.lastname: Moran
authors.forename: J Jack
authors.initials: JJ
authors.lastname: Lee
authors.forename: Ignacio I
authors.initials: II
authors.lastname: Wistuba
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D066246:ErbB Receptors / Q000235:genetics; D047628:Estrogen Receptor alpha / Q000378:metabolism*; D047629:Estrogen Receptor beta / Q000378:metabolism*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D015999:Multivariate Analysis; D009154:Mutation / Q000235:genetics; D016016:Proportional Hazards Models; D011980:Receptors, Progesterone / Q000378:metabolism*; D012044:Regression Analysis; D046888:Tissue Array Analysis
chemical_list: D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D011980:Receptors, Progesterone; D066246:ErbB Receptors
references.citation: Cancer Res. 2005 Feb 15;65(4):1598-605
references.pmid: 15735050
references.citation: Br J Cancer. 2001 Apr 20;84(8):1095-8
references.pmid: 11308260
references.citation: Br J Cancer. 2002 Jul 1;87(1):43-8
references.pmid: 12085254
references.citation: Cancer Res. 2005 Dec 15;65(24):11478-85
references.pmid: 16357156
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4130-5
references.pmid: 15024130
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4583-8
references.pmid: 17671145
references.citation: Am J Pathol. 2000 Jan;156(1):29-35
references.pmid: 10623650
references.citation: J Mol Endocrinol. 2000 Feb;24(1):145-55
references.pmid: 10657006
references.citation: Lung Cancer. 2002 Aug;37(2):153-9
references.pmid: 12140138
references.citation: Anticancer Res. 1996 Nov-Dec;16(6B):3803-6
references.pmid: 9042261
references.citation: Mol Cancer Ther. 2007 Oct;6(10):2626-33
references.pmid: 17913855
references.citation: Annu Rev Med. 2008;59:429-42
references.pmid: 17716025
references.citation: Anticancer Res. 2005 Nov-Dec;25(6C):4693-8
references.pmid: 16334162
references.citation: Steroids. 2007 Feb;72(2):135-43
references.pmid: 17276470
references.citation: Lung Cancer. 2009 Apr;64(1):51-9
references.pmid: 18701186
references.citation: Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5813-24
references.pmid: 14676101
references.citation: Trends Endocrinol Metab. 2005 Jul;16(5):222-7
references.pmid: 15936211
references.citation: Clin Cancer Res. 2005 Jul 15;11(14):5084-9
references.pmid: 16033821
references.citation: Chest. 1997 Jun;111(6):1710-7
references.pmid: 9187198
references.citation: Curr Mol Med. 2007 Feb;7(1):3-14
references.pmid: 17311529
references.citation: Lung Cancer. 2008 Jan;59(1):88-94
references.pmid: 17905466
references.citation: Mol Cell Endocrinol. 2002 Feb 25;188(1-2):125-40
references.pmid: 11911952
references.citation: Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):83-7
references.pmid: 16540736
references.citation: Steroids. 2005 May-Jun;70(5-7):372-81
references.pmid: 15862820
references.citation: Endocr Rev. 2004 Dec;25(6):869-98
references.pmid: 15583021
references.citation: Mol Endocrinol. 2003 Feb;17(2):203-8
references.pmid: 12554748
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Curr Oncol Rep. 2004 Jul;6(4):259-67
references.pmid: 15161576
references.citation: Cancer Res. 2002 Apr 1;62(7):2141-50
references.pmid: 11929836
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Int J Cancer. 1996 Jul 29;67(3):357-64
references.pmid: 8707409
references.citation: Cancer Res. 2005 Sep 1;65(17):7568-72
references.pmid: 16140919
references.citation: Int J Cancer. 2006 Jan 15;118(2):257-62
references.pmid: 16231326
references.citation: Nat Med. 1999 Oct;5(10):1130-1
references.pmid: 10502813
references.citation: Arch Pathol Lab Med. 2000 Oct;124(10):1467-70
references.pmid: 11035577
references.citation: J Clin Oncol. 2009 Jan 20;27(3):411-7
references.pmid: 19064969
references.citation: Cancer Res. 2005 Feb 15;65(4):1459-70
references.pmid: 15735034
references.citation: Lancet Oncol. 2004 Mar;5(3):174-81
references.pmid: 15003201
references.citation: J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
references.pmid: 15741570
references.citation: Mol Endocrinol. 2002 Jan;16(1):100-15
references.pmid: 11773442
references.citation: Cancer Res. 2005 Jul 15;65(14):6450-8
references.pmid: 16024650
references.citation: J Thorac Cardiovasc Surg. 2005 Oct;130(4):979-86
references.pmid: 16214508
references.citation: Nat Rev Cancer. 2007 Oct;7(10):778-90
references.pmid: 17882278
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7280-7
references.pmid: 16243798